Onco创新和Kuano启动了一个量子-AI实验,以加速针对固态肿瘤的癌症药物开发。 Onco-Innovations and Kuano launch a quantum-AI pilot to accelerate cancer drug development targeting solid tumors.

加拿大一家生物技术公司Onco-Inventions与Kuano Ltd公司共同发起了一个试点项目,以加速开发其PNKP抑制剂技术,重点是固体肿瘤的A83B4C63化合物。 Onco-Innovations, a Canadian biotech firm, has launched a pilot project with Kuano Ltd. to accelerate development of its PNKP inhibitor technology, focusing on compound A83B4C63 for solid tumors. 合作将Kuano的量子准备就绪分析与Onco的AI驱动药物发现结合起来,分析抑制剂如何与PNKP酶结合,目的是改进药物设计、药效和临床前期进展。 The collaboration combines Kuano’s quantum-ready analytics with Onco’s AI-driven drug discovery to analyze how the inhibitor binds to the PNKP enzyme, aiming to improve drug design, potency, and preclinical advancement. 该项目贯穿于2025年Q4,预计将产生结构模型、机械洞察力和数据,以支持今后的量子药物发现,包括毒性预测和基因化合物设计。 The project, running through Q4 2025, is expected to generate structural models, mechanistic insights, and data to support future quantum-enabled drug discovery, including toxicity prediction and generative compound design.